Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LZB:NYSE exploding $2.20 $6 book value cash flow positive retail laggard no brainer
http://ih.advfn.com/p.php?pid=nmona&cb=1243873518&article=36304600&symbol=NY%5ELZB
LZB:NYSE Moving next FBN 2.12 DD clean conservative balance sheet Lazy Boy did I mention 4.2 mill Short
AGEN APPROVED Cancer Drug $.73 +$.04
AGEN cancer drug APPROVED for Russia, EU approval expected later this year. 2 more huge neww events = $2 by June 10
1) ASCO conference
2) June 10 Conference Call
http://seekingalpha.com/article/140293-antigenics-contrary-indicator?source=yahoo
AGEN APPROVED Cancer Drug $.73 +$.04
AGEN cancer drug APPROVED for Russia, EU approval expected later this year. 2 more huge neww events = $2 by June 10
1) ASCO conference
2) June 10 Conference Call
http://seekingalpha.com/article/140293-antigenics-contrary-indicator?source=yahoo
AGEN Russia Cancer Vaccine exploding $.66
http://biz.yahoo.com/e/090527/agen8-k.html
1 PE ratio: ATSG:NASDAQ $1.34 +$.04
Reported $.18 in latest quarter
Massive insider buying
http://finance.yahoo.com/q/it?s=ATSG
1 PE ratio: ATSG:NASDAQ $1.34 +$.04
Reported $.18 in latest quarter
Massive insider buying
http://finance.yahoo.com/q/it?s=ATSG
1 PE ratio: ATSG:NASDAQ $1.20 +$.13
Reported $.18 in latest quarter
Massivre insider buying
http://finance.yahoo.com/q/it?s=ATSG
1 PE ratio: ATSG:NASDAQ $1.20 +$.13
Reported $.18 EPS in latest quarter
Massivre insider buying
http://finance.yahoo.com/q/it?s=ATSG
1 PE ratio: ATSG:NASDAQ $1.20 +$.13
Reported $.18 in latest quarter
Massivre insider buying
http://finance.yahoo.com/q/it?s=ATSG
Briggy, I have been early to the party on dozens of these small cap high fliers since early March, but TWB got in at $4.10.
I am just playing stocks I think can move a very fast 50 % in this market.. no more buy and holds in US stocks I am worried about US dollar. as a Canadian been raising Canadian cash big time.
Thanks will repost on Yahoo acknowledging your efforts. GREAT news. Long 45,000 shares.
TRIB:NASDAQ 3 forward PE
Why TRIB is my favorite health care buy on NASDAQ:
1) $.12 EPS in last quarter, slowest quarter of year. Should earn $.75 going forward.
2) As noted TRIB manufacturers diagnotic tests (many rapid tests) not drugs. With that said, its TRISTAT (three in one diabetes test) will be submitted to the FDA for CLIA waiver next month (use in doctor's offices) and it already has approval for hospital and clinics. It is the only 3 in 1 test, will be extremely competitive because it entitles the provider to a government subsidy (because it is 3 in 1) and at the last CC it was noted there will be a 65% net on the sales. The market is $500 million worldwide.
Also, their Destiny Max (hardware plus reagents) should be FDA approved in the next 90 days. It is approved in Europe. It replaces old equipment TRIB was selling, is state of the art, and will add revenue.
Weekend "No Brainer" Tip: TRIB:NASDAQ 3 forward PE
Why TRIB is best health care buy on NASDAQ:
1) $.12 EPS in last quarter, slowest quarter of year. Should earn $.75 going forward.
2) As noted TRIB manufacturers diagnotic tests (many rapid tests) not drugs. With that said, its TRISTAT (three in one diabetes test) will be submitted to the FDA for CLIA waiver next month (use in doctor's offices) and it already has approval for hospital and clinics. It is the only 3 in 1 test, will be extremely competitive because it entitles the provider to a government subsidy (because it is 3 in 1) and at the last CC it was noted there will be a 65% net on the sales. The market is $500 million worldwide.
Also, their Destiny Max (hardware plus reagents) should be FDA approved in the next 90 days. It is approved in Europe. It replaces old equipment TRIB was selling, is state of the art, and will add revenue.
Long a TON of TWB $6 short term
Picked up TWB too as retail has been hot sector, done well with RUTH and RUS and TUES.
Also look at FRZ:NYSE volume exploding an Ice distribitor makes all its earmings in April - September historically very profitable was a $12 IPO now $2.30
Summer: FRZ exploding Ice distribitor makes all its earmings in April - September historically very profitable was a $12 IPO now $2.30
Summer: FRZ exploding Ice distribitor makes all its earmings in April - September historically very profitable was a $12 IPO now $2.30
HEB $2 Monday HUGE Conference Call
CC Summary:
Hemispherics are stand alone financed now for five years ( a 18.3MM private finacing on very favourable terms was just announced today, and their 28MM revolving credit facility remains operational), and 'they had 6 million in cash to use before this new offering took place. 3 million of the warrants have only a 45-day strike price of 1.10. Obviously those are in place in case Ampligen receives approval for CFS treatment.' (RonnieD}
They expect to get FDA approval on their main drug (Ampligen) shortly, are well in advanced stages of trials in Japan for this and others, they have a very wide range of applications for their drugs including MS and Chronic Fatigue Syndrome (a $90Bn drain on the U.S. economy per annum), and expect to partner with a heavyweight this year on the marketing and delivery side.
The stock is breaking out to new highs in reaction to the successful financing, and new business opportunities on the near horizon.
The whole thing is being guided by the person who pioneered Interferon out of Johns Hopkins, the CEO himself.
He says today:
'We have emerged as a very serious player in the influenza space. We have emerged as a serious player in the vaccine space."
We are focusing on PANDEMIC APPLICATIONS....
"We see the current woldwide influenza problem as a major, major opportunity for Hemispherics in catastrophic applications... we are a serious,
Can anyone post a summary of CC highlights, especially on Ampligen
BZ:NYSE Laggard $1.6 trading at 1 X cash flow
http://seekingalpha.com/article/136404-boise-more-than-paper-profits?source=yahoo
BZ:NYSE Laggard $1.6 trading at 1 X cash flow
http://seekingalpha.com/article/136404-boise-more-than-paper-profits?source=yahoo
BZ:NYSE Laggard $1.6 trading at 1 X cash flow
http://seekingalpha.com/article/136404-boise-more-than-paper-profits?source=yahoo
BKUNA $1.25 +$.53 May 14 deadline for bid submissions. looking for $2 easy by Thursday
http://www.reuters.com/article/marketsNews/idCAN1154851420090511?rpc=44
BKUNA Royal Bank of Canada bid I bought this stock this morning wnen I saw at 8:30 EST canadian business network reported Royal Bank of Canada making a bid
BKUNA Royal Bank of Canada bid I bought this stock this morning wnen I saw at 8:30 EST canadian business network reported Royal Bank of Canada making a bid
Yes, DVAX lid about to blow off IMO. With 25 MM float this could be $3 in a nanosecond.
Why DXAX $2 + next week:
I thought you'd be interested in this; as I'm sure you're aware, DVAX is awaiting notification to find out if Heplisav will have the clinical hold removed by the FDA or perhaps even be granted FDA approval. What's tricky is figuring out just when that will be. DVAX has been stating, in their last few releases that they expect this issue to be resolved in the first half of 2009. The FDA Advisory Committee meets quarterly. So when is their next meeting?
May 20-21, 2009. Merry Christmas
http://www.fda.gov/cber/advisory/vrbp/vrbpmain.htm
Why DXAX $2 + next week:
I thought you'd be interested in this; as I'm sure you're aware, DVAX is awaiting notification to find out if Heplisav will have the clinical hold removed by the FDA or perhaps even be granted FDA approval. What's tricky is figuring out just when that will be. DVAX has been stating, in their last few releases that they expect this issue to be resolved in the first half of 2009. The FDA Advisory Committee meets quarterly. So when is their next meeting?
May 20-21, 2009. Merry Christmas
http://www.fda.gov/cber/advisory/vrbp/vrbpmain.htm
WSTL:NASDAQ $.5- +15% One of last quality NASDAQ penny laggards:
-$200 MM + annual sales
-Insider Buying
-Beautiful balance sheet $.66 cash / share
http://finance.yahoo.com/q/bs?s=WSTL
In last earnings release CEO states costs being cut on return to profit:
http://www.westell.com/news-2009/westell-technologies-reports-fiscal-third-quarter-2009-results.html
Positive seeking alpha article:
http://seekingalpha.com/article/132193-will-westell-pull-out-of-its-tail-spin?source=yahoo
WSTL:NASDAQ $.50 +15% One of last quality NASDAQ penny laggards:
-$200 MM + annual sales
-Insider Buying
-Beautiful balance sheet $.66 cash / share
http://finance.yahoo.com/q/bs?s=WSTL
In last earnings release CEO states costs being cut on return to profit:
http://www.westell.com/news-2009/westell-technologies-reports-fiscal-third-quarter-2009-results.html
Positive seeking alpha article:
http://seekingalpha.com/article/132193-will-westell-pull-out-of-its-tail-spin?source=yahoo
WSTL:NASDAQ $.5- +15% One of last quality NASDAQ penny laggards:
-$200 MM + annual sales
-Insider Buying
-Beautiful balance sheet $.66 cash / share
http://finance.yahoo.com/q/bs?s=WSTL
In last earnings release CEO states costs being cut on return to profit:
http://www.westell.com/news-2009/westell-technologies-reports-fiscal-third-quarter-2009-results.html
Positive seeking alpha article:
http://seekingalpha.com/article/132193-will-westell-pull-out-of-its-tail-spin?source=yahoo
LEE:NYSE $.61 + 25% LEE will thrive because...
1. They have embraced additional revenue streams outside of the traditional models of newspapers. Two of their properties have started recycling companies.
2. Their business model to stay in small to midsize markets which are more in tune with traditional media.
3. They have embraced the interent with a partnership with Yahoo hotjobs.
4. Cash flow and EBITDA is still very strong. Writedowns of assets, refinance charges etc have hurt the the eps but will rebound in late 2009. The .19 pershare dividend cut alone will help the eps.
5. Refinanced debt in early 2009, no covenant issues.
6. Large insider buying.
LEE:NYSE $.61 + 25% LEE will thrive because...
1. They have embraced additional revenue streams outside of the traditional models of newspapers. Two of their properties have started recycling companies.
2. Their business model to stay in small to midsize markets which are more in tune with traditional media.
3. They have embraced the interent with a partnership with Yahoo hotjobs.
4. Cash flow and EBITDA is still very strong. Writedowns of assets, refinance charges etc have hurt the the eps but will rebound in late 2009. The .19 pershare dividend cut alone will help the eps.
5. Refinanced debt in early 2009, no covenant issues.
6. Large insider buying.
TRIB:NASDAQ Flu test kits. 5 Forward PE
TRIB is by FAR cheapest profitable flu play.
JUST ANNOUNCED $.12 EPS for last quarter and forecast earnings to increase. TRIB has skyrocketed in past flu outbreaks. TRIB will go to $8 even without Swine flu issue tyey should earn $.75 for 2009.
http://www.trinitybiotech.com/Products/A...
TRIB:NASDAQ Flu test kits. 5 Forward PE
TRIB is by FAR cheapest profitable flu play.
JUST ANNOUNCED $.12 EPS for last quarter and forecast earnings to increase. TRIB has skyrocketed in past flu outbreaks. TRIB will go to $8 even without Swine flu issue tyey should earn $.75 for 2009.
http://www.trinitybiotech.com/Products/A...
HSKA Profitable NASDAQ penny EXPLODING
HSKA was historically a $2 stock when profitable now $.57 and exploding on profit.
http://finance.yahoo.com/q/is?s=HSKA&annual
HSKA Profitable NASDAQ penny EXPLODING
HSKA was historically a $2 stock when profitable now $.57 and exploding on profit.
http://finance.yahoo.com/q/is?s=HSKA&annual
DNDN: CEGE Monster sympathy play goinh huhe after hours. Many say CEGE drug is superior to DNDN Huge insider buys
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=CEGE&mkttype=after&symbol=CEGE&symbol=DNDN